CTOs on the Move

United Veterinary Care

www.unitedveterinarycare.com

 
Your vision. Our resources. Together we can build a bright future for your practice and the veterinary industry as a whole.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Steve Collins
Chief Information Officer Profile

Similar Companies

Boriken Neighborhood Health Ctr.

The Boriken - School Health Program has provided primary care services in East Harlem schools since 1983 The Program operates clinics which offer medical and mental health services in three elementary schools (Public Schools 7, 112 and 155).

Gen-Diagnostics

Gen-Diagnostics Incorporated is a San Juan Capistrano, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Missouri Highlands Health Care

Missouri Highlands Health Care is non-profit, community-owned organization. Unlike traditional health care practices, Missouri Highlands has a governing body, composed of volunteers from the communities we serve.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic